Prostat Kanseri Tanısında Thiol/Disülfid Dengesi PSA'ya Ek Bir Serum Belirteç Olarak Güvenilir midir?

Year 2019, Volume: 3 Issue: 3, 231 - 235, 26.10.2019

Ramazan Topaktaş , Ahmet Ürkmez Musab Ali Kutluhan Ali Akkoç , Emrah Özsoy Özcan Erel

https://doi.org/10.30565/medalanya.551320

Abstract

Amaç: Bu çalışmada, prostat kanseri tanısında thiol/disülfid dengesinin prostat spesifik antijene (PSA) ek bir serum markırı olarak değerlendirmeyi amaçladık. 

Hastalar ve Yöntemler: Prospektif çalışmamız PSA düzeyi 2.5-20 ng / mL olan, rektal muayenede malignite şüphesi olmayan ve prostat iğnesi biyopsisi yapılan toplam 174 hasta üzerinde yapıldı. Dışlama kriterleri sonrası çalışmamıza toplam 75 hasta dahil edildi. Biyopsi öncesi hastaların serum PSA, thiol ve disülfid düzeyleri kaydedildi. Çalışmamıza patoloji sonucu prostat kanseri olan 25 hasta, patoloji sonucu kronik prostatit olan 25 hasta ve patoloji sonucu benign prostat hiperplazisi (BPH) olan 25 hasta dahil edildi. 

Bulgular: Prostat kanseri grubunda total ve native thiol seviyeleri BPH ve kronik prostatit gruplarından daha yüksekti; ancak, istatistiksel anlamlı bir farklılık gözlenmedi (p> 0.05). Prostat kanseri alt grupları incelendiğinde, total ve native thiol seviyelerinin Gleason skoru 7, 8 ve 9 olan hastalarda, Gleason skoru 6 olanlara göre daha yüksek olduğu saptandı; ancak, istatistiksel anlamlı bir fark gözlenmedi (p> 0.05). 

Sonuç: Thiol seviyeleri prostat kanseri grubunda, benign hastalık (BPH ve kronik prostatit) gruplarından daha yüksekti; bu seviyeler aynı zamanda Gleason skoru yüksek olan grupta (Gleason 7, 8 veya 9), Gleason skoru düşük olan (Gleason 6) gruba göre daha yüksekti; ancak, bu farklılıklar istatistiksel olarak anlamlı değildi. 

Keywords

Prostat kanseri, Thiol, Disülfid, Tanı, Prostat spesifik antijen

Is Thiol/Disulphide Homeostasis Reliable as an Additional Serum Marker to PSA in the Diagnosis of Prostate Cancer?

Abstract

Aim: We aimed to investigate thiol/disulphide homeostasis as an additional serum marker to prostate specific antigen (PSA) in the diagnosis of prostate cancer. 

Patients and Methods: Prospective study was conducted among 174 patients with PSA levels of 2.5–20 ng/mL without suspicion of malignancy in rectal examination and who underwent prostate needle biopsy. A total of 75 patients were included in our study after exclusion criteria. Serum PSA, thiol, and disulphide levels of the patients were recorded prior to biopsy. In this study, 25 patients with pathology results indicating prostate cancer, 25 randomly selected patients with pathology results indicating chronic prostatitis, and 25 randomly selected patients with pathology results indicating benign prostate hyperplasia (BPH) were included. 

Results: Total and native thiol levels were higher in prostate cancer group than in BPH and chronic prostatitis groups; however, no statistically significant difference was observed (p> 0.05). When prostate cancer sub-groups were investigated, total and native thiol levels were noted to be higher in patients with a Gleason score of 7, 8, and 9 than in those with a Gleason score of 6; however, no statistically significant difference was observed (p> 0.05). 

Conclusions: Thiol levels were higher in prostate cancer group than in benign disease (BPH and chronic prostatitis) groups; these levels were also higher in group with high Gleason scores (Gleason 7, 8, or 9) than in group with a low Gleason score (Gleason 6); however, these differences were not statistically significant. 

Keywords

Prostate cancer, Thiol, Disulphide, Diagnosis, Prostatic specific antigen

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. PMID: 30620402
• 2. Yassin A, Nettleship JE, Talib RA, Almehmadi Y, Doros G. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19(1):64-9. PMID: 26742589
• 3. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab. 2000;11(2):54-60. PMID: 10675891
• 4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16. PMID: 2442609
• 5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324(17):1156-61. PMID: 1707140
• 6. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147(3):841-5. PMID: 1371559
• 7. Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem. 2014;47(18):326-32. PMID: 25304913
• 8. Altıparmak IH, Erkuş ME, Sezen H, Demirbag R, Gunebakmaz O, Kaya Z et al. The relation of serum thiol levels and thiol/disulphide homeostasis with the severity of coronary artery disease. Kardiol Pol. 2016;74(11):1346-53. PMID: 27221962
• 9. Ergin M, Aydin C, Yurt EF, Cakır E, Erel O. The variation of disulfides in the progression of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2018 Jan 29. [Epub ahead of print] doi: 10.1055/s-0044-100376. PMID: 29378378
• 10. Karatas F, Acat M, Sahin S, et al. The prognostic and predictive significance of serum thiols and disulfide levels in advanced non-small cell lung cancer. Aging Male. 2019 Jan 16:1-10. [Epub ahead of print] doi: 10.1080/13685538.2018.1559805. PMID: 30651017
• 11. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-19. PMID: 19297565
• 12. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-32. PMID: 22228146
• 13. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8. PMID: 19297566
• 14. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;15;366(11):981-90. PMID: 22417251
• 15. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-35. PMID: 25108889
• 16. Coban S, Doluoglu OG, Keles I, Demirci H, Turkoglu AR, Guzelsoy M et al. Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia. Aging Male. 2016;19(2):124-7. PMID: 26872869
• 17. Marcus PM, Ogden SL, Gren LH, Childs JC, Pretzel SM, Lamerato LE et al. Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Prev Med. 2014;67:82-8. PMID: 25038532
• 18. Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer. 2011;117(6):1210-9. PMID: 20960520
• 19. Sonmez MG, Kozanhan B, Deniz ÇD, Göger YE, Kilinç MT, Neşelioglu S et al. Is oxidative stress measured by thiol/disulphide homeostasis status associated with prostate adenocarcinoma? Cent Eur J Immunol. 2018;43(2):174-9. PMID: 30135630
• 20. Hanikoglu F, Hanikoglu A, Kucuksayan E, Alisik M, Gocener AA, Erel O et al. Dynamic thiol/disulphide homeostasis before and after radical prostatectomy in patients with prostate cancer. Free Radic Res. 2016;50(1):79-84. PMID: 27620702
• 21. Da Silveira RA, Hermes CL, Almeida TC, Bochi GV, De Bona KS, Moretto MB et al. Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer. Clin Lab. 2014;60(10):1703-8. PMID: 25651717
• 22. Mastella AK, Moresco RN, da Silva DB, Becker AM, Duarte MM, Giovelli LL et al. Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. Biomed Pharmacother. 2009;63(10):762-6. PMID: 19375269